ELMOD1

Summary

ELMOD1 (ELMO domain containing 1, HGNC:25334) is a protein-coding gene on chromosome 11q22.3, encoding ELMO domain-containing protein 1 (Q8N336). Acts as a GTPase-activating protein (GAP) toward guanine nucleotide exchange factors like ARL2, ARL3, ARF1 and ARF6, but not for GTPases outside the Arf family.

Enables GTPase activator activity. Predicted to act upstream of or within cilium assembly and protein transport. Predicted to be active in Golgi apparatus; cilium; and glutamatergic synapse.

Source: NCBI Gene 55531 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 3
• Clinical variants (ClinVar): 56 total
• MANE Select transcript: NM_018712

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25334
Approved symbol	ELMOD1
Name	ELMO domain containing 1
Location	11q22.3
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp547C176
Ensembl gene	ENSG00000110675
Ensembl biotype	protein_coding
OMIM	615456
Entrez	55531

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 5 protein_coding, 3 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000265840, ENST00000443271, ENST00000524378, ENST00000527036, ENST00000529675, ENST00000531234, ENST00000534236, ENST00000959906, ENST00000959907

RefSeq mRNA: 3 — MANE Select: NM_018712 NM_001130037, NM_001308018, NM_018712

CCDS: CCDS44723, CCDS44724, CCDS76472

Canonical transcript exons

ENST00000265840 — 12 exons

Exon	Start	End
ENSE00000746412	107650335	107650403
ENSE00000795444	107654172	107654222
ENSE00001005031	107650885	107650908
ENSE00001101496	107655933	107656066
ENSE00001132697	107647468	107647601
ENSE00001185310	107635636	107635765
ENSE00001185313	107631580	107631677
ENSE00001185317	107630700	107630728
ENSE00001630985	107665025	107666779
ENSE00002181706	107591147	107591409
ENSE00003523396	107630417	107630562
ENSE00003530847	107618105	107618206

Expression profiles

Bgee: expression breadth ubiquitous, 192 present calls, max score 98.79.

FANTOM5 (CAGE): breadth broad, TPM avg 7.1725 / max 309.4794, expressed in 458 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
116504	2.7963	306
116500	2.6177	230
116506	0.9254	123
116507	0.3846	92
116505	0.1323	73
116502	0.1084	60
116501	0.1066	62
116503	0.1012	60

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lateral nuclear group of thalamus	UBERON:0002736	98.79	gold quality
upper arm skin	UBERON:0004263	98.19	gold quality
cortical plate	UBERON:0005343	97.84	gold quality
Brodmann (1909) area 46	UBERON:0006483	97.54	gold quality
cerebellar vermis	UBERON:0004720	97.49	gold quality
endothelial cell	CL:0000115	96.91	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.69	gold quality
lateral globus pallidus	UBERON:0002476	96.61	gold quality
pons	UBERON:0000988	96.22	gold quality
middle temporal gyrus	UBERON:0002771	96.18	gold quality
superior vestibular nucleus	UBERON:0007227	95.89	gold quality
substantia nigra pars compacta	UBERON:0001965	95.79	gold quality
superior frontal gyrus	UBERON:0002661	95.38	gold quality
parietal lobe	UBERON:0001872	95.15	gold quality
postcentral gyrus	UBERON:0002581	94.89	gold quality
occipital lobe	UBERON:0002021	94.78	gold quality
primary visual cortex	UBERON:0002436	94.57	gold quality
substantia nigra pars reticulata	UBERON:0001966	94.23	gold quality
prefrontal cortex	UBERON:0000451	93.97	gold quality
nucleus accumbens	UBERON:0001882	93.80	gold quality
medulla oblongata	UBERON:0001896	93.43	gold quality
frontal cortex	UBERON:0001870	93.15	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	93.15	gold quality
frontal lobe	UBERON:0016525	93.15	gold quality
upper leg skin	UBERON:0004262	92.84	gold quality
Brodmann (1909) area 9	UBERON:0013540	92.68	gold quality
entorhinal cortex	UBERON:0002728	92.52	gold quality
neocortex	UBERON:0001950	92.30	gold quality
cerebral cortex	UBERON:0000956	92.23	gold quality
ventral tegmental area	UBERON:0002691	91.64	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-75367	yes	40.32
E-ANND-3	yes	5.01

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

136 targeting ELMOD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420

Literature-anchored findings (GeneRIF, showing 3)

• The non-opioid sigma-1 receptor (S1R) was identified as a novel effector of GAP activity of ELMOD1-3 proteins as its direct binding to either ELMOD1 or ELMOD2 resulted in loss of GAP activity. (PMID:24616099)
• Data suggest that GPR124 promotes cell adhesion via interaction with Elmo1-Dock180 and intersectin 1/2; this constitutes a previously unrecognized heteromeric complex that is putatively involved in GPR124-dependent adhesive/angiogenic responses in vascular endothelial cells. (GPR124 = G-protein coupled receptor 124; Elmo1 = ELMO domain-containing protein 1; Dock180 = dedicator of cytokinesis protein 1 180 kDa) (PMID:28600358)
• ELMOD1 mutation segregates with intellectual disability and autism spectrum disorder in Iranian family. (PMID:31327155)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	elmod1	ENSDARG00000062056
mus_musculus	Elmod1	ENSMUSG00000041986
rattus_norvegicus	Elmod1	ENSRNOG00000009054

Paralogs (5): ELMO2 (ENSG00000062598), ELMO3 (ENSG00000102890), ELMOD3 (ENSG00000115459), ELMO1 (ENSG00000155849), ELMOD2 (ENSG00000179387)

Protein

Protein identifiers

ELMO domain-containing protein 1 — Q8N336 (reviewed: Q8N336)

All UniProt accessions (2): Q8N336, E9PLM8

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a GTPase-activating protein (GAP) toward guanine nucleotide exchange factors like ARL2, ARL3, ARF1 and ARF6, but not for GTPases outside the Arf family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8N336-1	1	yes
Q8N336-2	2
Q8N336-3	3

RefSeq proteins (3): NP_001123509, NP_001294947, NP_061182* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006816	ELMO_dom	Domain
IPR050868	ELMO_domain-containing	Family

Pfam: PF04727

UniProt features (4 total): splice variant 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N336-F1	90.80	0.72

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 122 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, BENPORATH_ES_WITH_H3K27ME3, PEREZ_TP63_TARGETS, chr11q22, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, EFC_Q6, GOBP_CILIUM_ORGANIZATION, E4F1_Q6, GOBP_ORGANELLE_ASSEMBLY, PEREZ_TP53_AND_TP63_TARGETS, GOBP_CELL_PROJECTION_ORGANIZATION, YNGTTNNNATT_UNKNOWN, LEE_TARGETS_OF_PTCH1_AND_SUFU_DN, TGGAAA_NFAT_Q4_01

GO Biological Process (3): protein transport (GO:0015031), cilium assembly (GO:0060271), intracellular protein localization (GO:0008104)

GO Molecular Function (1): GTPase activator activity (GO:0005096)

GO Cellular Component (4): Golgi apparatus (GO:0005794), cilium (GO:0005929), glutamatergic synapse (GO:0098978), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transport	1
intracellular protein localization	1
establishment of protein localization	1
axoneme assembly	1
intraciliary transport involved in cilium assembly	1
cilium organization	1
protein localization to cilium	1
organelle assembly	1
trans-Golgi to periciliary membrane compartment transport	1
plasma membrane bounded cell projection assembly	1
ciliary transition zone assembly	1
macromolecule localization	1
GTPase activity	1
enzyme activator activity	1
GTPase regulator activity	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1
synapse	1
cell junction	1

Protein interactions and networks

STRING

1042 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ELMOD1	ELMOD3	Q96FG2	791
ELMOD1	ARL2	P36404	569
ELMOD1	POGLUT3	Q7Z4H8	554
ELMOD1	SLC35F2	Q8IXU6	540
ELMOD1	RASA1	P20936	516
ELMOD1	DOCK1	Q14185	513
ELMOD1	ARL3	P36405	501
ELMOD1	ELMO2	Q96JJ3	490
ELMOD1	ELMO3	Q96BJ8	486
ELMOD1	ELMO1	Q92556	433
ELMOD1	ARF6	P26438	400
ELMOD1	TBC1D24	Q9ULP9	364
ELMOD1	PIP5K1B	P78518	362
ELMOD1	CYTH2	Q99418	359
ELMOD1	MYSM1	Q5VVJ2	351

IntAct

8 interactions, top by confidence:

A	B	Type	Score
ELMOD1	LDHC	psi-mi:“MI:0914”(association)	0.530
ELMOD1	S100A10	psi-mi:“MI:0915”(physical association)	0.400
ELMOD1	RHOA	psi-mi:“MI:0915”(physical association)	0.400
ELMOD1	THG1L	psi-mi:“MI:0915”(physical association)	0.370
ITM2B	ILVBL	psi-mi:“MI:0914”(association)	0.350
TMED7	ATP9A	psi-mi:“MI:0914”(association)	0.350

BioGRID (18): SELENBP1 (Affinity Capture-MS), LRRC15 (Affinity Capture-MS), PKP3 (Affinity Capture-MS), LGALS3 (Affinity Capture-MS), DSG4 (Affinity Capture-MS), ELMOD1 (Two-hybrid), LRRC15 (Affinity Capture-MS), LDHC (Affinity Capture-MS), PKP3 (Affinity Capture-MS), ELMOD1 (Affinity Capture-MS), ELMOD1 (Proximity Label-MS), DSG4 (Affinity Capture-MS), PBLD (Affinity Capture-MS), ELMOD1 (Affinity Capture-MS), LDHC (Affinity Capture-MS)

ESM2 similar proteins: A1A5Q4, A1L3F5, B0I564, B1AY13, O15327, O75934, Q0IIE6, Q28DG8, Q29RL1, Q2IA00, Q4R4D7, Q4R6T7, Q4R708, Q5NVD7, Q5RA60, Q5RAX7, Q5RBT3, Q5U1Z0, Q5VZE5, Q5ZHV2, Q62717, Q6DDI6, Q6DFL5, Q6DKG0, Q6GLR7, Q6PBE2, Q6PE87, Q6PHQ8, Q7SYB2, Q7T322, Q7ZXA8, Q86UW7, Q86VS3, Q8BMG7, Q8BYR5, Q8C9J3, Q8CDG3, Q8CF97, Q8CJF7, Q8IYR0

Diamond homologs: Q08DZ3, Q09292, Q0IIE6, Q3V1U8, Q54RS7, Q54UP9, Q54VR8, Q54YW1, Q5NVD7, Q5XIQ2, Q8BGF6, Q8IZ81, Q8N336, Q91YP6, Q58DT5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

56 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2656 predictions. Top by Δscore:

Variant	Effect	Δscore
11:107591437:G:GT	donor_gain	1.0000
11:107617914:GC:G	donor_gain	1.0000
11:107618103:A:AG	acceptor_gain	1.0000
11:107618103:AGTT:A	acceptor_gain	1.0000
11:107618104:G:GG	acceptor_gain	1.0000
11:107618104:GTT:G	acceptor_gain	1.0000
11:107618104:GTTG:G	acceptor_gain	1.0000
11:107631678:G:GG	donor_gain	1.0000
11:107647463:TACA:T	acceptor_loss	1.0000
11:107647464:ACAG:A	acceptor_loss	1.0000
11:107647465:C:G	acceptor_gain	1.0000
11:107647466:A:AG	acceptor_gain	1.0000
11:107647466:AG:A	acceptor_loss	1.0000
11:107647467:G:GA	acceptor_gain	1.0000
11:107647467:GT:G	acceptor_gain	1.0000
11:107647467:GTT:G	acceptor_gain	1.0000
11:107647467:GTTA:G	acceptor_gain	1.0000
11:107647467:GTTAT:G	acceptor_gain	1.0000
11:107647597:TTGCA:T	donor_gain	1.0000
11:107647598:TGCA:T	donor_gain	1.0000
11:107647599:GCA:G	donor_gain	1.0000
11:107647599:GCAG:G	donor_gain	1.0000
11:107647600:CA:C	donor_gain	1.0000
11:107647601:AG:A	donor_loss	1.0000
11:107647602:G:GG	donor_gain	1.0000
11:107647603:TA:T	donor_loss	1.0000
11:107647604:AAG:A	donor_loss	1.0000
11:107647605:AGT:A	donor_loss	1.0000
11:107656067:G:GG	donor_gain	1.0000
11:107664478:G:GT	donor_gain	1.0000

AlphaMissense

2235 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:107647522:T:A	W159R	1.000
11:107647522:T:C	W159R	1.000
11:107647524:G:C	W159C	1.000
11:107647524:G:T	W159C	1.000
11:107647534:G:C	G163R	1.000
11:107647535:G:A	G163D	1.000
11:107647535:G:T	G163V	1.000
11:107647537:T:C	F164L	1.000
11:107647538:T:C	F164S	1.000
11:107647539:C:A	F164L	1.000
11:107647539:C:G	F164L	1.000
11:107647542:A:C	Q165H	1.000
11:107647542:A:T	Q165H	1.000
11:107647552:C:T	P169S	1.000
11:107647553:C:A	P169H	1.000
11:107647561:G:C	D172H	1.000
11:107647562:A:C	D172A	1.000
11:107647562:A:G	D172G	1.000
11:107647562:A:T	D172V	1.000
11:107647563:C:A	D172E	1.000
11:107647563:C:G	D172E	1.000
11:107647565:T:C	F173S	1.000
11:107647576:G:A	G177R	1.000
11:107647576:G:C	G177R	1.000
11:107647577:G:A	G177E	1.000
11:107647577:G:T	G177V	1.000
11:107655952:G:C	G240R	1.000
11:107665054:T:A	W288R	1.000
11:107665054:T:C	W288R	1.000
11:107665087:T:C	F299L	1.000

dbSNP variants (sampled 300 via entrez): RS1000002802 (11:107593838 T>C), RS1000108784 (11:107664276 T>C), RS1000151880 (11:107590364 C>G), RS1000156169 (11:107633856 C>G), RS1000209404 (11:107633638 G>A), RS1000211890 (11:107626952 T>G), RS1000217371 (11:107643252 A>C), RS1000259552 (11:107641623 C>T), RS1000263157 (11:107615297 G>A,T), RS1000291101 (11:107664599 T>C), RS1000370518 (11:107640319 A>G), RS1000394911 (11:107610200 C>A,T), RS1000404271 (11:107597996 C>A,T), RS1000445885 (11:107603290 A>G), RS1000482324 (11:107646304 G>A,T)

Disease associations

OMIM: gene MIM:615456 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Limited	Autosomal recessive

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006168_1	Pulse pressure x alcohol consumption interaction (2df test)	3.000000e-08
GCST007676_13	3-month functional outcome in ischaemic stroke (modified Rankin score)	4.000000e-06
GCST012485_9	Cerebral amyloid angiopathy x sex interaction in Alzheimer’s disease	7.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004329	alcohol drinking
EFO:0005763	pulse pressure measurement
EFO:0009603	stroke outcome severity measurement
EFO:0008343	sex interaction measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, increases expression	9
trichostatin A	affects cotreatment, increases expression	3
bisphenol A	increases methylation, decreases expression	2
mercuric bromide	increases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
sotorasib	decreases expression, affects cotreatment	1
propionaldehyde	increases expression	1
sodium arsenate	decreases expression, increases abundance	1
butyraldehyde	increases expression	1
hydroquinone	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
pentanal	increases expression	1
CGP 52608	increases reaction, affects binding	1
deguelin	decreases expression	1
fenpyroximate	decreases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
pyrimidifen	decreases expression	1
clothianidin	decreases expression	1
ICG 001	decreases expression	1
thifluzamide	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
trametinib	affects cotreatment, decreases expression	1
NVP-BKM120	affects cotreatment, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Arsenic Trioxide	decreases expression	1
Aldehydes	increases expression	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice